-葡萄糖共运输体2抑制剂是否降低了II型糖尿病患者与对比相关的急性损伤的风险?
Gizem Çabuk1, Kutluhan Eren Hazır1
1Department of Cardiology, Tepecik Training and Research Hospital, İzmir, Türkiye.
Anatolian journal of cardiology
|March 20, 2024
概括
在接受冠状动脉动脉扫描的糖尿病患者中,-葡萄糖共载体2 (SGLT2) 抑制剂显著降低了与对比相关的急性损伤. 这些患者也经历了更短的住院时间,突出显示了SGLT2抑制剂的保护性益处.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 糖尿病患者面临与对比相关的急性损伤 (CA-AKI) 的风险更高.
- -葡萄糖共运输体2 (SGLT2) 抑制剂已经证明了潜在的保护作用.
- 冠状动脉血管学手术存在CA-AKI的风险,特别是在脆弱人群中.
研究的目的:
- 研究SGLT2抑制剂对CA-AKI的预防作用.
- 评估SGLT2抑制剂对接受冠状动脉血管造影的糖尿病患者住院时间的影响.
- 为了比较患有SGLT2抑制剂的和没有SGLT2抑制剂的糖尿病患者的CA-AKI发病率.
主要方法:
- 这是一项涉及345名II型糖尿病患者的横截面单中心研究.
- 患者被分为两组:SGLT2抑制剂使用者 (n=133) 和非使用者 (n=212).
- 两组之间的CA-AKI发病率和住院时间的比较.
主要成果:
- 基线特征和对比度在各组之间是相似的.
- 与非使用者组 (26.4%) 相比,SGLT2抑制剂组 (9.0%) 的CA-AKI发病率明显较低.
- 在使用SGLT2抑制剂的患者中,住院时间显著缩短 (2.54天),而非使用者 (3.25天).
结论:
- SGLT2 抑制剂在接受冠心血管造影的糖尿病患者中显著降低了CA-AKI.
- 使用SGLT2抑制剂的糖尿病患者住院时间较短.
- 在这种患者群体中,SGLT2抑制剂提供了对CA-AKI的保护策略.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
199
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
199
Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
174
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
174
Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
Glucose Transporters
22.7K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.7K


